Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc is positioned for a positive outlook due to anticipated faster growth in the spine market, alongside increased sales from its Enabling Technologies segment, which could lead to improved profit margins. The company is expecting organic growth to enhance revenue guidance, notably with a strong performance in the US Spine market and an impressive 10% growth in Nevro sales in the fourth quarter. Furthermore, as Globus Medical integrates NuVasive and advances in manufacturing, significant gross margin expansion is projected, stabilizing EBITDA margins around 34-35% by 2026, which supports a strong financial foundation for the company.

Bears say

The analysis highlights several significant risks contributing to a negative outlook for Globus Medical's stock. Key concerns include potential sluggish growth in the spine market, revenue disruption related to ongoing mergers, and underperformance in Enabling Technologies sales, all of which could lead to a decline in operating margins and overall financial performance. Additionally, the company faces competitive pressures from newly focused spine franchises and risks associated with delayed market introductions for key products, further complicating its growth trajectory.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.